Fly News Breaks for January 26, 2017
Jan 26, 2017 | 12:31 EDT
Piper Jaffray analyst William Quirk says Natera's lawyers wrote a court letter yesterday saying that a settlement agreement with Bio-Reference is in the final stages. A royalty per Bio-Reference's ClariTest sold is possible, and a quick settlement a positive for Natera's legal spend, Quirk tells investors in a research note. He keeps an Overweight rating on the shares.
News For NTRA;BRLI From the Last 2 Days
May 24, 2022 | 08:09 EDT
Natera announced the appointment of Minetta Liu, as its new Chief Medical Officer of oncology. In this role, Liu will set the direction for the company's clinical and scientific roadmap in oncology, primarily to prove the clinical utility of Signatera and incorporate it into standard medical practice across tumor types. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic in Rochester, MN. In her role at Mayo, she also held a dual appointment in the Department of Laboratory Medicine and Pathology and served as co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine. In her new position as CMO, Liu will succeed Alexey Aleshin, who was recently appointed Natera's general manager of early cancer detection.